[1]方晨 郭鹤鸣 黄韵 陈小红 李思诚 刘翠平 胡吉.警惕肿瘤免疫治疗的内分泌系统不良反应[J].国际内分泌代谢杂志,2019,39(05):327-331,336.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
　Fang Chen,Guo Heming,Huang Yun,et al.Be aware of endocrinological side effects of cancer immunotherapy[J].International Journal of Endocrinology and Metabolism,2019,39(05):327-331,336.[doi:10.3760/cma.j.issn.1673-4157.2019.05.010]
点击复制

警惕肿瘤免疫治疗的内分泌系统不良反应()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
39
期数:
2019年05期
页码:
327-331,336
栏目:
综述
出版日期:
2019-09-20

文章信息/Info

Title:
Be aware of endocrinological side effects of cancer immunotherapy
作者:
方晨1 郭鹤鸣1 黄韵1 陈小红1 李思诚1 刘翠平2 胡吉1
1苏州大学附属第二医院内分泌科 215004; 2江苏省临床免疫研究所,苏州 215000
Author(s):
Fang Chen1;  Guo Heming1;  Huang Yun1;  Chen Xiaohong1;  Li Sicheng1;  Liu Cuiping2;  Hu Ji1
1Department of Endocrinology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China; 2Jiangsu Institute of Clinical Immunology, Suzhou 215000, China
关键词:
免疫检查点抑制剂;  内分泌疾病;  细胞毒性T淋巴细胞相关抗原-4;  程序性细胞死亡蛋白-1
Keywords:
Immune checkpoint inhibitor;  Endocrine disease;  Cytotoxic T lymphocyte antigen-4;  Programmed cell death protein-1
DOI:
10.3760/cma.j.issn.1673-4157.2019.05.010
摘要:
肿瘤免疫治疗中免疫检查点抑制剂(ICPi)已广泛应用于临床,它们通过阻断抑制T细胞功能的负调节因子来增强抗肿瘤作用。细胞毒性T淋巴细胞相关抗原-4(CTLA-4)抑制剂和程序性细胞死亡蛋白-1(PD-1)抑制剂的应用已经显著改善了一些晚期恶性肿瘤的预后,但也导致多种自身免疫性不良反应。内分泌疾病包括甲状腺功能紊乱、自身免疫性糖尿病和垂体炎等,已成为ICPi治疗中最常见的免疫相关不良事件之一。这些内分泌系统不良反应若不能及时发现和治疗,会影响患者治疗甚至危及生命。了解ICPi治疗相关性内分泌系统不良反应的临床特点、诊断及治疗,可增进临床医师在免疫治疗中对该类不良反应的认识。
Abstract:
In cancer immunotherapy, immune checkpoint inhibitors(ICPi)have been widely used. They enhance antitumour immunity by blocking negative regulators of T cell function.Cytotoxic T lymphocyte antigen-4(CTLA-4)and programmed cell death protein-1(PD-1)inhibitors have dramatically changed the outcome of patients with several advanced stage malignancies, but they also lead to a variety of autoimmune consequences. Endocrinopathies have emerged as one of the most common immune-related adverse events(irAEs)of ICPi therapy including thyroid dysfunction, autoimmune diabetes and hypophysitis, etc. These endocrinological side effects can affect the tumor treatment even be life-threatening if not promptly recognized and treated. Knowing the clinical characteristics, diagnosis and treatment of various ICPi related adverse reactions of endocrine system could enhance clinicians’ understanding of these adverse reactions in immunotherapy.

参考文献/References:

[1] Iorgulescu JB,Harary M,Zogg CK,et al.Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a National Cohort[J].Cancer Immunol Res,2018,6(9):1039-1045.DOI:10.1158/2326-6066.CIR-18-0067.
[2] Iyer PC,Cabanillas ME,Waguespack SG,et al Immune-related thyroiditis with immune checkpoint inhibitors[J].Thyroid,2018,28(10):1243-1251.DOI:10.1089/thy.2018.0116.
[3] Torino F,Corsello SM,Salvatori R.Endocrinological side-effects of immune checkpoint inhibitors[J].Curr Opin Oncol,2016,28(4):278-287.DOI:10.1097/CCO.0000000000000293.
[4] 林常松,郭梓,莫朝晖. Nivolumab致甲状腺功能减退症1例[J].中南大学学报(医学版),2019,44(2):222-224.DOI:10.11817/j.issn.1672-7347.2019.02.016.
[5] Orlov S,Salari F,Kashat L,et al.Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies[J].J Clin Endocrinol Metab,2015,100(5):1738-1741.DOI:10.1210/jc.2014-4560.
[6] Lee H,Hodi FS,Giobbie-Hurder A,et al.Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy[J].Cancer Immunol Res,2017,5(12):1133-1140.DOI:10.1158/2326-6066.CIR-17-0208.
[7] Yamauchi I,Sakane Y,Fukuda Y,et al.Clinical features of nivolumab-induced thyroiditis: a case series study[J].Thyroid,2017,27(7):894-901.DOI:10.1089/thy.2016.0562.
[8] Scott ES,Long GV,Guminski A,et al.The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma[J].Eur J Endocrinol,2018,178(2):173-180.DOI:10.1530/EJE-17-0810.
[9] Delivanis DA,Gustafson MP,Bornschlegl S,et al.Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J].J Clin Endocrinol Metab,2017,102(8):2770-2780.DOI:10.1210/jc.2017-00448.
[10] Azmat U,Liebner D,Joehlin-Price A,et al.Treatment of ipilimumab induced Graves’ disease in a patient with metastatic melanoma[J].Case Rep Endocrinol,2016,2016:2087525.DOI:10.1155/2016/2087525.
[11] Gan EH,Mitchell AL,Plummer R,et al.Tremelimumab-induced graves hyperthyroidism[J].Eur Thyroid J,2017,6(3):167-170.DOI:10.1159/000464285.
[12] Delivanis DA,Gustafson MP,Bornschlegl S,et al. Pembrolizumab-induced thyroiditis: comprehensive clinical review and insights into underlying involved mechanisms[J].J Clin Endocrinol Metab,2017,102(8):2770-2780.DOI:10.1210/jc.2017-00448.
[13] Torimoto K,Okada Y,Nakayamada S,et al.Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells[J].Thyroid,2017,27(10):1335-1336.DOI:10.1089/thy.2017.0062.
[14] Narita T,Oiso N,Taketomo Y,et al.Serological aggravation of autoimmune thyroid disease in two cases receiving nivolumab[J].J Dermatol,2016,43(2):210-214.DOI:10.1111/1346-8138.13028.
[15] Martin-Liberal J,Furness AJ,Joshi K,et al.Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report[J].Cancer Immunol Immunother,2015,64(6):765-767.DOI: 10.1007/s00262-015-1689-1.
[16] Yamazaki N,Kiyohara Y,Uhara H,et al.Phase Ⅱ study of ipilimumab monotherapy in Japanese patients with advanced melanoma[J].Cancer Chemother Pharmacol,2015,76(5):997-1004.DOI:10.1007/s00280-015-2873-x.
[17] Tsiogka A,Jansky GL,Bauer JW,et al.Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma[J].Melanoma Res,2017,27(5):524-525.DOI:10.1097/CMR.0000000000000384.
[18] Imagawa A,Hanafusa T,Awata T,et al.Report of the committee of the Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus(2012)[J].J Diabetes Investig,2012,3(6):536-539.DOI:10.1111/jdi.12024.
[19] Fife BT,Bluestone JA.Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways[J].Immunol Rev,2008,224:166-182.DOI:10.1111/j.1600-065X.2008.00662.x.
[20] Wang CJ,Chou FC,Chu CH,et al.Protective role of programmed death 1 ligand 1(PD-L1)in nonobese diabetic mice: the paradox in transgenic models[J].Diabetes,2008,57(7):1861-1869.DOI:10.2337/db07-1260.
[21] Ansari MJ,Salama AD,Chitnis T,et al.The programmed death-1(PD-1)pathway regulates autoimmune diabetes in nonobese diabetic(NOD)mice[J].J Exp Med,2003,198(1):63-69.DOI:10.1084/jem.20022125.
[22] Nagata M,Santamaria P,Kawamura T,et al.Evidence for the role of CD8+ cytotoxic T cells in the destruction of pancreatic beta-cells in nonobese diabetic mice[J].J Immunol,1994,152(4):2042-2050.
[23] Barroso-Sousa R,Barry WT,Garrido-Castro AC,et al.Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J].JAMA Oncol,2018,4(2):173-182. DOI:10.1001/jamaoncol.2017.3064.
[24] Caturegli P,Di Dalmazi G,Lombardi M,et al.Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series[J].Am J Pathol,2016,186(12):3225-3235.DOI:10.1016/j.ajpath.2016.08.020.
[25] Min L,Hodi FS,Giobbie-Hurder A,et al.Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis:a retrospective cohort study[J].Clin Cancer Res,2015,21(4):749-755.DOI:10.1158/1078-0432.CCR-14-2353.
[26] Faje AT,Sullivan R,Lawrence D,et al.Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma[J].J Clin Endocrinol Metab,2014,99(11):4078-4085.DOI:10.1210/jc.2014-2306.
[27] Ishikawa M,Oashi K.Case of hypophysitis caused by nivolumab[J].J Dermatol,2017,44(1):109-110.DOI:10.1111/1346-8138.13437.
[28] Kitajima K,Ashida K,Wada N,et al.Isolated ACTH deficiency probably induced by autoimmune-related mechanism evoked with nivolumab[J].Jpn J Clin Oncol,2017,47(5):463-466.DOI:10.1093/jjco/hyx018.
[29] Laurent S,Queirolo P,Boero S,et al.The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production[J].J Transl Med,2013,11:108.DOI:10.1186/1479-5876-11-108.
[30] Romano E,Kusio-Kobialka M,Foukas PG,et al.Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients[J].Proc Natl Acad Sci U S A,2015,112(19):6140-6145.DOI:10.1073/pnas.1417320112.
[31] Quirk SK,Shure AK,Agrawal DK.Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibodytherapy in metastatic melanoma[J].Transl Res,2015,166(5):412-424.DOI:10.1016/j.trsl.2015.06.005.
[32] Ryder M,Callahan M,Postow MA,et al.Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution[J].Endocr Relat Cancer,2014,21(2):371-381.DOI:10.1530/ERC-13-0499.
[33] Downey SG,Klapper JA,Smith FO,et al.Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade[J].Clin Cancer Res,2007,13(22 Pt 1):6681-6688.DOI:10.1158/1078-0432.CCR-07-0187.
[34] Albarel F,Gaudy C,Castinetti F,et al.Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma[J].Eur J Endocrinol,2015,172(2):195-204.DOI:10.1530/EJE-14-0845.
[35] Scott ES,Long GV,Guminski A,et al.The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpointinhibitors for metastatic melanoma[J].Eur J Endocrinol,2018,178(2):173-180.DOI:10.1530/EJE-17-0810.
[36] de Filette J,Andreescu CE,Cools F,et al.A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors[J].Horm Metab Res,2019,51(3):145-156.DOI:10.1055/a-0843-3366.
[37] Onesti CE, Barnabei A, Marchetti P, et al. Early onset of endocrine alterations during PD-1 blockade in advanced NSCLC patients[J].Ann Oncol,2017,28:ii28-ii51.
[38] Zeng MF,Chen LL,Ye HY,et al.Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: case report and review[J].Medicine(Baltimore),2017,96(44):e8426.DOI:10.1097/MD.0000000000008426.
[39] Brahmer JR,Lacchetti C,Schneider BJ,et al.Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(17):1714-1768.DOI:10.1200/JCO.2017.77.6385.

相似文献/References:

[1]崔雯锦,胡欣,韦晓,等.免疫检查点抑制剂诱发甲状腺功能紊乱的研究进展[J].国际内分泌代谢杂志,2021,41(01):33.[doi:10.3760/cma.j.cn121383-20200909-09019]
　Cui Wenjin,Hu Xin,Wei Xiao,et al.Progress in immune checkpoint inhibitors induced thyroid dysfunction[J].International Journal of Endocrinology and Metabolism,2021,41(05):33.[doi:10.3760/cma.j.cn121383-20200909-09019]
[2]崔雯锦,陈国芳,刘超.免疫检查点抑制剂相关内分泌疾病诊治研究进展[J].国际内分泌代谢杂志,2021,41(02):116.[doi:10.3760/cma.j.cn121383-20200331-03086]
　Cui Wenjin,Chen Guofang,Liu Chao..Progress in the diagnosis and treatment of immune checkpoint inhibitors related endocrine diseases[J].International Journal of Endocrinology and Metabolism,2021,41(05):116.[doi:10.3760/cma.j.cn121383-20200331-03086]
[3]舒惺贻,路明,章卫平,等.心磷脂参与线粒体稳态维持和功能调节的研究进展[J].国际内分泌代谢杂志,2024,44(01):43.[doi:10.3760/cma.j.cn121383-20230622-06041]
　Shu Xingyi,Lu Ming,Zhang Weiping,et al.Update of the involvement of cardiolipin in mitochondrial homeostasis maintenance and functional regulation[J].International Journal of Endocrinology and Metabolism,2024,44(05):43.[doi:10.3760/cma.j.cn121383-20230622-06041]

备注/Memo

备注/Memo:
通信作者:胡吉,Email:huji@suda.edu.cn
Corresponding author: Hu Ji, Email:huji@suda.edu.cn
基金项目:国家自然科学基金(81600607); 江苏省研究生科研与实践创新计划项目(SJCX18_0854)
Fund program:National Natural Science Foundation of China(81600607); Postgraduate Research & Practice Innovation Program of Jiangsu Province(SJCX18_0854)
更新日期/Last Update: 2019-09-20